about
Multidrug-resistant bacteria in solid organ transplant recipientsEfficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis.Methyl-hydroxylamine as an efficacious antibacterial agent that targets the ribonucleotide reductase enzymeInfluenza A H1N1/2009 infection in pediatric solid organ transplant recipients.Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease.Immunogenicity of pandemic influenza A H1N1/2009 adjuvanted vaccine in pediatric solid organ transplant recipients.Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosisImpact of hepatitis C virus infection on the risk of infectious complications after kidney transplantation: data from the RESITRA/REIPI cohort.Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial.Visceral leishmaniasis among liver transplant recipients: an overview.Executive summary. Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical MicrManagement of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) anClinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections.Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosidesEfficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditisTreatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum.Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety.Blood and tissue distribution of posaconazole in a rat model of invasive pulmonary aspergillosis.Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.Galactomannan enzyme immunoassay and quantitative Real Time PCR as tools to evaluate the exposure and response in a rat model of aspergillosis after posaconazole prophylaxis.Epidemiology and Immediate Indirect Effects of Respiratory Viruses in Lung Transplant Recipients: A 5-Year Prospective Study.Management of catheter-related Staphylococcus aureus bacteremia: when may sonographic study be unnecessary?Efficacy of anidulafungin in the treatment of experimental Candida parapsilosis catheter infection using an antifungal-lock technique.Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA.Rhodococcus equi pneumonia in patients infected with the human immunodeficiency virus. Report of 2 cases and review of the literature.Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients.10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation.Influenza vaccination during the first 6 months after solid organ transplantation is efficacious and safe.Nontuberculous mycobacterial meningitis: report of two cases and review.Ventilator-associated respiratory infection following lung transplantation.Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors.Daptomycin is safe and effective for the treatment of gram-positive cocci infections in solid organ transplantation.Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort.Daptomycin is effective as antibiotic-lock therapy in a model of Staphylococcus aureus catheter-related infection.Liver biopsy-related infection in liver transplant recipients: A current matter of concern?Response to acyclovir in two cases of herpes zoster leukoencephalitis and review of the literature.Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients.Immunosuppressive therapy and infection after kidney transplantation.
P50
Q26822729-2A62AADB-9A65-4CCF-B299-BB70AC8F677DQ28345165-B6E68B37-A92D-4AFE-A2EF-DB51AA772733Q28544447-FE96E80A-BF03-4DCC-BFE4-AD6E327FBA68Q30421504-379BC9E8-B0FC-40B0-B6AE-97D116BEA08CQ30422526-5468A5A5-C780-4463-BC9A-AD05DB568895Q30430823-8A0CB721-4DD9-4861-941D-08D4A157A1DCQ33883785-68613E88-8427-41E3-8B4A-1DAC230DA784Q34003488-5C444D51-FFDE-40D3-9879-9E4497184B17Q34157089-977E0E7E-D180-486E-986B-3313A5828405Q37331906-3F973C36-89E9-4D52-A42C-C54926926DC1Q38092937-FD13A5E7-348A-418A-96DB-D731E58F857FQ38092938-0BBFBB0F-EB69-45E6-91F3-BCCBC5FA066EQ38280283-6931FFBD-D3A1-4985-AC72-5828348186DCQ38882205-B46C2BEC-85D8-4517-9149-234C05302E4DQ39470313-B318A958-5D02-4593-97F1-AD1D15BF2312Q39477095-00D04110-7EC3-4D99-8200-8A873AC7F27CQ39781254-F561A335-E507-46FA-81A0-87421DDBFBDEQ40004415-72144BFE-137D-4D61-A4CE-68EBF67CEA46Q40435009-9D1389C6-71F4-45DC-A5EC-4E5D9F4C4A13Q40452469-9876B166-D40E-4337-AE24-296FDB454B0FQ40492198-7FFB5CB7-044A-40F8-883D-69E04BD139F8Q40544268-E1C67E8F-97C4-4BA5-B255-870CC1BD0FF6Q40546602-06D57C31-4DDC-4F4F-AB40-2814A4212502Q40625328-653EFF9F-FFB6-4E79-A9E3-576870042F05Q40650646-8151C603-394D-4B07-BAEB-9E2F4E2E8E94Q40657179-A2331A51-F97B-48D1-B367-2D1B089EF57FQ40855547-38F2A389-F1B8-41F5-9F8F-BEA8E119DEBEQ40867351-3587C125-C13E-4A82-81A6-8832D495B0ECQ41015559-6119A38B-36A4-4805-BBBC-BF3D722E7A8DQ41077583-BD7FFE2A-C725-4FA2-827A-BE1B5238B350Q41254141-3DBA97AB-C2F9-4568-B5B5-1D38D262AD38Q41682759-3518C15E-2012-4D2E-B109-093441F375DEQ42214580-8FB49921-2FA2-4E18-9FDA-4D61E069D112Q42215009-4848F2E9-7627-44B2-8729-CF429A0BCE63Q42216221-951CE26B-5133-4B4F-93B4-1A47C6DCEBC3Q42233449-98A03A80-5C9B-44E2-BAD2-3A680B0B0B80Q42233966-BDDC8F85-C0B1-4ED3-9FB1-51C09FC6A9F1Q42540317-EC8E1D84-4512-4AF9-B7DB-82AD28FA0CF0Q42611743-C618FB7E-F3A8-474E-84B3-E6ECE024FCB1Q43018607-09BA235B-2D59-4370-9792-9F7CAEBDDCA0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Joan Gavaldà
@ast
Joan Gavaldà
@en
Joan Gavaldà
@es
Joan Gavaldà
@nl
Joan Gavaldà
@sl
type
label
Joan Gavaldà
@ast
Joan Gavaldà
@en
Joan Gavaldà
@es
Joan Gavaldà
@nl
Joan Gavaldà
@sl
prefLabel
Joan Gavaldà
@ast
Joan Gavaldà
@en
Joan Gavaldà
@es
Joan Gavaldà
@nl
Joan Gavaldà
@sl
P106
P1153
7005686002
P21
P31
P3835
dr-joan-gavald
P496
0000-0002-9829-3141